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Abstract. Flavonoids, a subclass of polyphenols, have been
shown to be effective against several types of cancer, by
decreasing proliferation and inducing apoptosis. Therefore,
the aim of the present study was to assess the anti‑carci‑
nogenic potential of luteolin on HeLa human cervical
cancer cells, through the use of a cell viability assay, DNA
fragmentation assay, mitochondrial membrane potential
assay, cell cycle analysis using Annexin/PI staining and flow
cytometry, gene expression analysis and a protein profiling
array. Luteolin treatment exhibited cytotoxicity towards
HeLa cells in a dose‑ and time‑dependent manner, and its
anti‑proliferative properties were confirmed by accumula‑
tion of luteolin‑treated cells in sub‑G1 phases. Cytotoxicity
induced by luteolin treatment resulted in apoptosis, which
was mediated through depolarization of the mitochondrial
membrane potential and DNA fragmentation. Furthermore,
luteolin treatment increased the expression of various
proapoptotic genes, including APAF1, BAX, BAD, BID,
BOK, BAK1, TRADD, FADD, FAS, and Caspases 3 and 9,
whereas the expression of anti‑apoptotic genes, including
NAIP, MCL‑1 and BCL‑2, was decreased. Cell cycle regula‑
tory genes, including CCND1, 2 and 3, CCNE2, CDKN1A,
CDKN2B, CDK4 and CDK2, were decreased following
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treatment. Expression of TRAILR2/DR5, TRAILR1/DR4,
Fas/TNFRSF6/CD95 and TNFR1/TNFRSF1A, as well as
pro‑apoptotic proteins, including BAD, BAX and Cytochrome
C were consistently increased, and the expression of anti‑
apoptotic proteins, HIF1α, BCL‑X, MCL1 and BCL2, were
found to be decreased following treatment. Expression of
AKT1 and 2, ELK1, PIK3C2A, PIK3C2B, MAPK14, MAP3K5,
MAPK3 and MAPK1 was significantly decreased at the tran‑
scriptional level. Expression of GSK3b (p‑ser9), PRAS 40
(p‑Ther246), BAD (p‑ser112), PTEN (p‑ser380), AKT
(p‑ser473), ERK2 (p‑Y185/Y187), RISK2 (p‑ser386), P70S6k
(p‑Thr421/ser424), PDK1(p‑ser241), ERK1 (p‑T202/Y204)
and MTOR (p‑ser2448) was downregulated and expression of
P53 (p‑ser241) and P27(p‑Thr198) was upregulated by luteolin
in a dose‑dependent manner, indicating its anti‑proliferative
and apoptosis enabling properties, and this may have been
mediated via inhibition of the AKT and the MAPK pathways.
Introduction
A major challenge with conventional cancer treatments,
including chemotherapy, is the genotypic and phenotypic
heterogeneity of cancer cells, and non‑selective cytotoxicity of
these treatment regimens, and this limits their use, increasing
the risk of cancer reoccurrence (1,2). Therefore, experi‑
mental evidences need to be accumulated on plant‑derived
chemopreventative strategies, which may be used as adju‑
vants for improved cancer management. Chemopreventative
agents (synthetic and natural) consist of nonsteroidal
anti‑inflammatory drugs (sulindac, aspirin and celecoxib) (3)
and FDA‑approved drugs, including Tamoxifen, Raloxifene
and HPV vaccines (Cervarix and Gardasil), which all show
potential anticancer effects. However, these adjuvants have
also demonstrated adverse side effects in patients (4‑6).
Considering the constraints of these agents, studies are focused
on identifying alternatives based on plant‑derived compounds,
which exhibit decreased toxicity with higher efficacy for the
treatment of cancer (7‑9).
Notably, an epidemiological study proposed that 30% of
cancer types can be avoided by a healthy diet (2), and the
consumption of certain fruits and vegetables may decrease
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the risk of cancer onset (5,10,11). Several flavonoids extracted
from various plants have been shown to exert anticancer prop‑
erties (5,7), exhibiting regulatory effects on several molecular
mechanisms, including their ability to increase the activity of
free radical scavenging enzymes, and increase anti‑prolifera‑
tive and anti‑inflammatory responses (7,12,13). Furthermore,
flavones, a subclass of flavonoids have been demonstrated
to possess anticancer effects through decreasing cancer cell
proliferation by downregulation of various pro‑apoptotic
proteins, including nuclear factor‑κ B along with modulation
of aberrant PI3K/AKT and MAPK/P38 signaling (14‑18).
Apoptosis is the desired outcome when treated with these
agents, and if the means by which apoptosis is induced is
determined, the efficacy of novel agents targeting these mech‑
anisms may be assessed. Apoptosis is primarily mediated by
the death receptor pathway and mitochondrial pathway. The
death receptor family, which is comprised of tumor necrosis
factor receptors, including TRAIL‑R2/DR5, TRAIL‑R1/DR4,
TNFRI/TNFRSF1A, Fas/TNFRSF6/CD95, Fas and DR6 may
initiate the extrinsic pathway, and BCL2 family members,
including Bad, Bak, Bax, Bid, Bik (pro‑apoptotic molecules),
and Bcl‑XL and Bcl‑2 (anti‑apoptotic members) are involved
in the mitochondrial pathway (19‑21).
Luteolin (3,4,5,7‑tetrahydroxy flavone) is a flavone
found in vegetables and fruits, including parsley, carrots,
artichoke, celery and several spices (including thyme and
oregano) (14,16,17,22‑25). Several studies have demonstrated
the anti‑inflammatory, anti‑microbial, anti‑diabetic and
anti‑carcinogenic properties of luteolin (23,26‑28). Luteolin
has been demonstrated to exhibit anticancer effects against
several types of cancer cell lines, including liver (HepG2), colon
(HT29), lung (LNM35) and breast cancer (MDA‑MB‑231)
cells, and is a potent HDAC inhibitor (16,19). Luteolin induces
apoptosis and cell cycle arrest by increasing expression of Bax,
Caspase 3 and Caspase 9, as well as the MEK‑ERK pathway,
whilst concomitantly decreasing Bcl‑2 expression in A549
lung cancer cells (18). Luteolin also possesses anti‑prolifera‑
tive effects against A549 lung cancer cells by arresting the cell
cycle at the G2 phase and initiating programmed cell death
via the mitochondrial pathway, which is mediated though
activation of JNK and inhibition of NF‑κ B (22,29). Luteolin
suppresses the MAPK/AKT/PI3K pathway, and NF‑kB and
STAT3 signalling in several types of cancer cell lines, and
also decreases the expression of matrix metalloproteins and
β3 integrin in B16F10 and A431 melanoma cell lines, thereby
inhibiting EMT (17,20,22,24,30,31).
Notably, flavonoids including luteolin have been reported
to inhibit tumor cell proliferation and apoptosis (14‑19) in
various cancer cell lines e.g., HPV‑18‑associated cells and lung
cancer cell (17,18). However, there is lack of scientific evidence
to review luteolin as a probable anticancer agent. Therefore,
the present study aimed to investigate the extensive molecular
mechanism through which luteolin induces anticancer effects
on HeLa cell as an apoptosis inducer by targeting various
molecular targets; tumor inhibitors and promoters: DAPK1,
TP53, TP73, PTPRRR and TERT; cell cycle regulatory genes:
CDK2, CCNE2, CCND2 and CCND; pro and anti‑apoptotic
genes: BAD, BID, BOK, BAX, Bcl2, Caspases 3, 7, 8 and 9;
receptors and pathways genes: FASLG, FAS, TNFRS10‑B,
MTOR, MAPK, PIK3CA, AKT1, ELK1, FOXO1 and FOXO3,

and to further associate it with the modulation of phosphory‑
lated proteins in luteolin‑treated HeLa cells to enhance the
acceptance of luteolin as a potential anticancer agent.
Material and methods
Cell culture and drug preparation. Information of every
important process that ensues in human cells whether normal
or abnormal has depended to a large extent on using HeLa cells
and they have also proved to be the best model for cervical
cancer (32); therefore, HeLa cells were used for this study.
Human cervical cancer HeLa cells were cultured in Dulbecco's
modified Eagle's medium (DMEM; Sigma‑Aldrich; Merck
KGaA), supplemented with 10% FBS (Sigma‑Aldrich; Merck
KGaA), 100 µg/ml amphotericin (Sigma‑Aldrich; Merck
KGaA) and 100 µg/ml streptomycin (Sigma‑Aldrich; Merck
KGaA), and cells were cultured at 37˚C in a humidified incu‑
bator with 5% CO2.
Luteolin (molecular weight, 286.24 g/mol) was purchased
from Sigma‑Aldrich (Merck KGaA) and diluted to a concen‑
tration of 69.87 mM using dimethyl sulfoxide (DMSO; stock
solution), which was then further diluted using DMEM
(without FBS) to a concentration of 1 mM, which was used to
make the working concentrations of 1‑40 µM.
MTT assay. MTT assay (Sigma‑Aldrich; Merck KGaA) was
used to study the cytotoxic effects of luteolin on HeLa cells.
In brief, 1x104 cells/well were plated onto a 96‑well plate and
treated as follows: Blank control, DMSO control (0.11%), posi‑
tive control (cisplatin 5 µM) and luteolin‑treated (1‑40 µM);
and treatment was performed for 24 or 48 h, after which
images were captured. Subsequently, plates were decanted,
and the cells were incubated with MTT at final concentration
of 5 mg/ml (dissolved in PBS) at 37˚C for 2‑4 h, the MTT was
discarded, 100 µl DMSO was added to the wells and plates
were incubated at 37˚C for 30 min in the dark. Viable cells
convert the tetrazolium salt into insoluble formazan violet crys‑
tals that is quantified using a colorimeter at 570 nm. A graph
was plotted by dividing the absorbance of luteolin‑treated
cells with that of DMSO controls. Data are presented as the
mean ± standard deviation of three independent repeats.
Nuclear staining of HeLa cells with propidium iodide (PI)
following luteolin treatment. PI staining of cells treated with
luteolin for different concentrations was performed to assess
morphological variations in the nucleus in cells undergoing
apoptosis. In total, ~2.5x105 cells were seeded onto glass cover‑
slips and treated with luteolin for 24 or 48 h. The cells were
then washed with 1x PBS (pH 7.4) twice and a mixture of ice
cold methanol:acetone (1:1) was used to fix the cells at ‑20˚C
for 10 min followed by staining with PI (10 mg/ml in PBS) for
30 sec in the dark at room temperature, and the cover slips
were subsequently mounted on glass slides. The images were
captured at 515 nm using a fluorescent microscope (Olympus
Corporation) at x40 magnification.
DNA fragmentation assay. Inter‑nucleosomal DNA disinte‑
gration is one of the primary features of apoptosis. During
apoptosis, nucleases are activated causing fragmentation
of nuclear chromatin into 50‑300 kbp fragments (33). The
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ApoTarget™ Quick Apoptotic DNA Ladder Detection kit
(cat. no. #KHO1021; Invitrogen; Thermo Fisher Scientific,
Inc.) was used for rapid extraction of chromosomal DNA of
untreated cells, and cells treated with 5, 10 and 20 µM luteolin
for 48 h, according to the manufacturer's protocol. The frag‑
mented DNA was extracted from cells and run on a horizontal
electrophoresis gel containing ethidium bromide and the DNA
was resolved on a 1.2% agarose gel.
Tetramethyl rhodamine, ethyl ester (TMRE) mitochondrial
membrane potential assay. A TMRE Mitochondrial
Membrane Potential assay kit (cat. no. ab113852; Abcam)
was used to assess the mitochondrial membrane potential. In
total, ~5x103 HeLa cells were plated onto clear bottom 96‑well
plates and treated with 5, 10 and 20 µM luteolin for 48 h at
room temperature. TMRE at a final concentration of 400 nM
was used and the cells were incubated in the dark for 30 min
at room temperature. Following washing several times with
the wash buffer provided with the aforementioned kit, the
plate was read on a fluorescence microplate spectrophotom‑
eter (Ex/Em=549/575 nm; Synergy H1 Bioteck Plate Reader)
and images were captured using a fluorescent microscope
(Progress Fluorescent Microscope; Olympus Corporation) at
x40 magnification.
Apoptosis detection using FITC‑conjugated Annexin
V/PI. Quantitation of the apoptosis was performed using a
FITC‑conjugated Annexin V/PI assay kit (cat. no. ab 14085;
Abcam) and analyzed using a flow cytometer. In brief,
2x105 cells were plated onto six‑well plates, and cells were
treated with 5, 10 and 20 µM luteolin for 48 h at 37˚C. Treated
and untreated cells were collected and washed with PBS and
resuspended in 500 µl binding buffer, followed by staining with
PI (50 µg/ml) and FITC‑conjugated Annexin V (10 mg/ml) for
15 min at room temperature in the dark, and the cells were
analyzed using a BD FACS‑Aria™ III Flow cytometer (BD
Biosciences). Flow cytometry data were analyzed using the
FlowJo software (FlowJo LLC; Version 10.1).
Cell cycle analysis by flow cytometry. HeLa cells were treated
with 0, 5, 10 and 20 µM luteolin for 48 h, and all the cells
(floating and attached) were collected. This was followed by
washing with 1x PBS and fixed with absolute ethanol at ‑20˚C
overnight. The following day, cells were washed with 1x PBS
and staining with PI (1 mg/ml), containing 0.1% citrate buffer,
Triton X‑100 and 0.5% RNase for 30 min at room temperature.
BD FACS‑Aria™ III Flow cytometer (BD Biosciences) was
used to analyze the cells for DNA content, and FlowJo soft‑
ware (FlowJo LLC; version 10.1) was used for data analysis.
Gene expression analysis using TaqMan arrays. RNA extraction
was performed on luteolin‑treated HeLa cells (10 and 20 µM
for 48 h at 37˚C) and untreated cells according to the manufac‑
turer's protocol using a GenElute Mammalian Genomic Total
RNA kit (Sigma‑Aldrich; Merck KGaA). Extracted total RNA
was quantified using Nanodrop (Thermo Fisher Scientific, Inc.).
RNA was then subjected to first strand synthesis, according to
the manufacturer's protocol, using an Applied Biosystems™
High‑Capacity cDNA Reverse Transcription kit (Applied
Biosystems; Thermo Fisher Scientific, Inc.).
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TaqMan® Gene Expression assays are a comprehensive
collection of pre‑designed, pre‑formulated primer and probe
sets to perform quantitative gene expression studies (Apoptosis
Array and oncogene array (cat. nos. 4414072 and 4391524).
TaqMan® Gene Expression assays that were manufactured and
stocked in advance were used to detect the expression of genes
associated with cell cycle signaling pathways and apoptosis in
the treated and untreated cells. A total of 10 µl cDNA with a
concentration of 100 ng per well and 10 µl master mix provided
in the kit was used. Expression analysis was performed
according to the manufacturer's protocol. The qPCR array was
run on a thermocycler (QuantiStudio3, Applied Biosystems,
USA) with the following reaction conditions: Enzyme activa‑
tion at 95˚C for 10 min and 40 cycles, denaturation at 95˚C for
15 sec, annealing at 60˚C for 1 min. Results were analyzed
by the 2‑ΔΔCq method using DataAssist™ software version 3.01
(Thermo Fisher Scientific, Inc.) as previously described (34).
Caspase 3 activity. Caspases are the final executioners of
apoptosis and Caspase‑3 serves a role in the extrinsic and
intrinsic pathways of apoptosis (35). A Caspase‑3 Activity kit
(cat. no. CASP 3C; Sigma‑Aldrich; Merck KGaA) was used. A
total of 1 x106 cells were plated and treated (5, 10 and 20 µM
luteolin at 37˚C for 48 h) with various concentrations of
luteolin. Cell pellets were taken and resuspended in the lysis
buffer (1X) at a concentration of 1X 107 cell/100 µl and incu‑
bated for 30 min, prior to being centrifuged at 12,000 x g for
20 min at 4˚C. The lysates of the DMSO control and treated
(5, 10 and 20 µM luteolin) HeLa cells and the assay were set up
according to the manufacturers' protocol. The plate was incu‑
bated overnight at room temperature and read at 405 nm, and
fold‑changes were calculated by comparing the treated sample
reading with the DMSO control. The experiment was repeated
3 times and all results are expressed as mean ± standard devia‑
tion of three independent experiments.
Determination of protein expression using a proteome profiler
array. To determine the expression of genes associated with
apoptosis and cell cycle progression at the protein level, a
protein profiler array was purchased from R&D Systems, Inc.
(cat. no. ARY009). The cells were treated with 10 and 20 µM
luteolin for 48 h at 37˚C and the lysis was performed with
lysis buffer. The assay was performed according to the manu‑
facturer's protocol to assess the expression of all the proteins
associated with apoptosis. Protein quantitation of lysates was
performed using a Pierce™ BCA Protein assay kit (Thermo
Fisher Scientific, Inc; cat. no. 23225). A further 400 µg protein
of the diluted cell lysate was used for each membrane, the
membranes were incubated with the lysates on a rocking
platform overnight at 2‑8˚C. The signal was developed using
Streptavidin‑HRP and chemiluminescent detection reagents.
Signal intensity was measured using a chemiluminescent
detector Gel Doc system (Bio‑Rad Laboratories, Inc.), and
analyzed using Image Lab software (version 6.1; Bio‑Rad
Laboratories, Inc.). The experiment was repeated three times
and the results are expressed as the mean ± standard deviation
from three independent experiments (*P<0.005).
Analysis of expression of phosphorylated AKT pathway
proteins. To determine the effect of luteolin treatment on
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Figure 1. Anti‑proliferative effect of luteolin on HeLa cells. (A) Induction of cytotoxicity by luteolin at various concentrations and time points. The graph
represents the dose‑ and time‑dependent decrease in cell viability of HeLa cells treated with 1‑40 µM luteolin for 24 and 48 h. For comparison, 0.11% DMSO
was used as the loading control and 5 µM cisplatin was used as the positive control. The 24 and 48 h treated samples were compared with 24 and 48 h DMSO
controls, respectively. The data are expressed as the mean ± standard deviation of three independent experiments. *P<0.05. The IC50 of luteolin was found to
be 20 µM at 48 h. (B) Microscopic images of HeLa cells treated with 10, 15 and 20 µM luteolin for 24 and 48 h. Cells exhibited a characteristic rounding off
of the cells, indicating apoptosis. Magnification, x10. (C) Changes in nuclear morphology of treated HeLa cells (10 and 20 µM luteolin) compared with the
untreated controls. These nuclear changes were observed following staining with propidium iodide under a fluorescence microscope (magnification, x 40). A
dose‑dependent increase in the apoptotic index, characterized by features such as nuclear condensation, nuclear blebbing, nuclear fragmentation and apoptotic
bodies, was observed. Yellow, large and prominent nuclei; purple, nuclear fragmentation; green, blebbing; white, apoptotic bodies. (D) Luteolin induces DNA
fragmentation in a dose‑dependent manner in HeLa cells. Lane 5 shows the 100 bp ladders; lanes 1, 2, 3 and 4 show fragmentation of DNA in cells treated with
5, 10 and 20 µm luteolin and the control, respectively. The experiment was performed three times. DMSO, dimethyl sulfoxide.

proteins involved in the AKT pathway, a phosphorylated
AKT pathway array was obtained from Ray‑Biotech, Co., Ltd.
(cat. no. AAH‑AKT‑1‑8). The lysates of treated and untreated
cells were quantitated using a Pierce BCA assay (Thermo
Fisher Scientific, Inc.) and ~500 µg lysate was used on each
nitrocellulose membrane. To begin with, the membranes were
blocked with blocking buffer from the aforementioned kit,
followed by incubation with the cell lysate for 24 h, and the
assay was performed according to the manufacturer's protocol.
The chemiluminescent gel doc system (BioRad Laboratories,
Inc.) was used to capture the image of the blot and analysis was
performed using Image Lab software (version 6.1).
Statistical analysis. Statistical analysis was performed using
SPSS software (version 21; IBM Corp.). The data was analyzed
using one‑way analysis of variance followed by Tukey's HSD
post hoc test. All experiments were performed in triplicate.
Results are expressed as the mean ± standard deviation of
three separate experiments *P<0.05 was considered to indicate
a statistically significant difference.
Results
Luteolin inhibits the growth and proliferation of HeLa cells.
HeLa cells treated with varying concentrations of luteolin
(1‑40 µM for 24 or 48 h) exhibited a dose and time‑dependent
decrease in the viability of HeLa cells when compared with the
untreated DMSO control. When cells were treated with 20 µM
luteolin for 48 h, ~50% cell death was observed (Fig. 1A).

Luteolin induced substantial morphological changes in HeLa
cells, including rounding off of the cells and subsequent
detachment of the cells from the surface, and the changes
became more significant as the dose of luteolin was increased
(Fig. 1B).
Luteolin induces nuclear morphological abnormalities and
causes DNA fragmentation in HeLa cells. HeLa cells treated
with 10 and 20 µM luteolin exhibited condensation and
disintegration of nuclear material, blebbing and formation of
apoptotic bodies and nuclear debris, which increased with
concentration, while the untreated HeLa cells possessed a
distinct and prominent nucleus (Fig. 1C). Furthermore, the
observation that luteolin induced apoptosis was supported by
the results of a DNA laddering assay in HeLa cells. Treatment
of HeLa cells with 5, 10 and 20 µM luteolin for 48 h resulted
in fragmentation of DNA. A typical DNA ladder‑like pattern
was observed in all the treated samples when compared with
the controls upon gel electrophoresis (Fig. 1D).
Luteolin treatment arrests cell cycle progression of HeLa cells
at sub‑G1 phases. Inhibition of proliferation and growth may
be a result of cell cycle arrest. Analysis of cell cycle progres‑
sion was performed on luteolin‑treated cells using PI staining
and flow cytometry. Luteolin induced accumulation of cells
at the G2/M phase when treated with 5 µM, and when treated
with 10 and 20 µM, accumulation of cells was observed at
sub‑G1 phases, and ~50% of cells were arrested when treated
with 20 µM luteolin for 48 h, with a decrease in the number of
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Figure 2. Luteolin induces cell cycle arrest in HeLa cells in sub‑G1 phases. (A) DNA contents were analyzed by flow cytometry following treatment with
different concentrations of luteolin (0, 5, 10 and 20 µM) for 48 h. (B) Percentage of cells in the G0/G1, S and G2/M phases of the cell cycle are compared
between the 5, 10, 20 µM treated HeLa cells and dimethyl sulfoxide control cells. The results are presented as the mean ± standard deviation of three indepen‑
dent experiments *P<0.05.

cells in the S and G2/M phases when compared with controls
wherein a normal distribution of cells was observed (Fig. 2).
In the present study, luteolin treatment increased the sub‑G1
peak, which is an indicator of endonuclease activation and
apoptosis induction due to DNA fragmentation, which appears
to be the crucial anti‑proliferative mechanism of luteolin treat‑
ment (36).
Luteolin induces early and late apoptosis. Annexin
V‑FITC and PI were used for the detection of early and late
apoptosis. Annexin V‑stained cells were considered early
apoptotic cells, and cells stained with PI and annexin V
and were considered late apoptotic cells. The percentage
of viable cells decreased from 90.5% in the control cells to
65.4 and 47.9% when treated with 10 and 20 µM luteolin,
respectively, for 48 h. Additionally, there was an increase
in early apoptotic cells from 2.89% in control samples to
9.75 and 12.4% when treated with 10 and 20 µM luteolin. A
notable increase in the proportion of late apoptotic cells was
detected, increasing from 1.89% in in the untreated samples
to 7.85 and 14% when treated with 10 and 20 µM luteolin
48 h, respectively (Fig. 3).
Luteolin decreases the mitochondrial membrane potential of
HeLa cells. Mitochondrial membrane potential is a reliable
measure of cell stress and apoptosis, as it is compromised early
during the stress response and a good indicator of ongoing
cell death. Several dyes may be used to detect mitochondrial
membrane potential, which allows flexibility in wavelengths
and use in combination with other fluorescence markers. In
the present study, TMRE was used. The percentage of TMRE
fluorescence was calculated compared with the control; 84, 64
and 56% of cells fluoresced with TMRE when HeLa cells were

treated with 5, 10 and 20 µM luteolin for 48 h, respectively
(Fig. 4).
Luteolin inhibits cell cycle progression by modulation of cell
cycle regulatory genes. Following treatment of HeLa cells with
5, 10 and 20 µM luteolin for 48 h, the untreated and treated cells
were subjected to cell cycle progression analysis. The results
demonstrated that 5 µM luteolin induced G2/M phase arrest
in HeLa cells, and when treated with 20 µM luteolin, there
was a substantial accumulation of cells at sub G1 phases. This
was further verified by assessing the expression of cell cycle
regulatory genes (oncogene array, cat. no. 4369514); down‑
regulation of cell cycle regulatory genes, including CCND1,
CCND2, CCND3, CCNE2, CDKN1A, CDKN2B, CDK4 and
CDK2, was observed. All these genes serve an important role
in the G1 phase transition. Additionally, telomerase reverse
transcriptase (TERT) expression was decreased and PTPRR
expression was significantly increased when treated with
10 and 20 µM luteolin. TERT adds repeat sequences of DNA
(TTAGGG) to the end of chromosomes, thereby increasing the
replicative properties, and its inhibition controls proliferation,
while PTPRR inhibits ERK and MAPK pathways. FOXO1
and FOXO3 expression was also upregulated, and they serve
an important role in apoptosis [Fig. 5A; RQ (relative quantita‑
tion)] values are presented in Table I).
Luteolin increases apoptosis in HeLa cells. HeLa cells treated
with 10 and 20 µM luteolin for 48 h along with untreated cells
were used to assess gene expression of apoptotic genes using
a TaqMan Array (apoptosis array; cat. no. 4414072). Gene
expression levels of APAF1, BID, BAK1, BOK, BAD, BAX,
NOD1, NOD2, BCL10 and BCL2L14, as well as Caspase‑3,
Caspase‑7 and Caspase‑9 increased (10 µM, RQ≥1.4; 20 µM,

6

RAINA et al: LUTEOLIN TRIGGERS APOPTOSIS AND INHIBITS PROLIFERATION OF HELA CELLS

Figure 3. Evaluation of apoptosis using Annexin V‑PI double staining following treatment of HeLa cells with 5, 10 and 20 µM luteolin for 24 and 48 h and
DMSO control cells. (A) Representative flow cytometry dot plots of apoptosis. In all four plots, viable cells are seen in the left lower quadrant (FITC‑/PI‑), early
apoptotic cells in the right lower quadrant (FITC+/PI‑), and late apoptotic cells in the right upper quadrant (FITC+/PI+). (B) Quantification of the proportion
of cells in different stages of apoptosis, as determined by flow cytometry. The proportion of early and late apoptotic cells increased in a dose‑dependent
manner, compared with DMSO control cells. Data are presented as the mean ± standard deviation of three independent experiments *P<0.05. DMSO, dimethyl
sulfoxide.

Figure 4. Luteolin decreases the membrane potential of HeLa cells in a concentration‑dependent manner. (A) HeLa cells were treated with 5, 10 and 20 µM
luteolin for 48 h, and the mitochondrial membrane potential was determined using TMRE staining and a fluorescent microscope (magnification, x40).
(B) TMRE fluorescence of treated cells was compared with the untreated control cells and the results are expressed as the percentage of fluorescence. Data are
presented as the mean ± standard deviation of three independent experiments *P<0.05.
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Table I. Relative quantitation values of cell cycle regulatory genes and pathway genes in HeLa cells following 10 and 20 µM
luteolin treatment for 48 h.
Genes

Gene ensemble no.

CDK4
Hs00175935_m1
ESR1
Hs01046816_m1
MTOR
Hs00234522_m1
PIK3C2B
Hs00898499_m1
		
CCNE2
Hs00372959_m1
CCND3
Hs00236949_m
CDK2
Hs01548894_m1
MAPK3
Hs00385075_m1
AKT2
Hs01086102_m1
ELK1
Hs00428286_g1
CCND1
Hs00765553_m1
MAPK1
Hs01046830_m1
AKT1
Hs00178289_m1
TERT
Hs00972650_m1
PIK3CA
Hs00907957_m1
CCND2
Hs00153380_m1
MAPK14
Hs00176247_m1
MAP3K5
Hs00178726_m1
PIK3CD
Hs00192399_m1
TP53
Hs01034249_m1
FOXO3
Hs00818121_m1
FOXO1
Hs00231106_m1
TP73
Hs01056231_m1
PTPRR
Hs00373136_m

Gene description

Luteolin 10 µM

Luteolin 20 µM

Cyclin dependent kinase inhibitor 1A
Estrogen receptor 1
Mechanistic target of rapamycin
Phosphatidylinositol‑4‑phosphate 3‑kinase
catalytic subunit type 2 beta
Cyclin E2
Cyclin D3
Cyclin‑dependent kinase 2
Mitogen‑activated protein kinase 3
AKT serine/threonine kinase 2
ELK1C
Cyclin D1
Mitogen‑activated protein kinase 1
AKT serine/threonine kinase 1
Telomerase reverse transcriptase
Phosphatidylinositol‑4C
Cyclin D2
Mitogen‑activated protein kinase 14
Mitogen‑activated protein kinase kinase kinase 5
Phosphatidylinositol‑4
Tumor protein p53
Forkhead box O3
Forkhead box O1
Tumor protein p73
Protein tyrosine phosphatase

0.06
0.12
0.23
0.37

0.04
0.04
0.18
0.10

0.39
0.45
0.45
0.45
0.45
0.48
0.50
0.50
0.52
0.53
0.53
0.60
0.60
0.69
0.71
1.20
1.60
1.90
2.80
9.50

0.28
0.24
0.42
0.19
0.30
0.25
0.31
0.18
0.31
0.40
0.35
0.25
0.32
0.40
0.23
2.23
4.10
4.70
5.40
10.00

RQ≥2), while expression of BCL2 and MCL‑1 expression was
decreased in a dose‑dependent manner (20 µM, RQ≤0.5),
and NAIP demonstrated a marginal decrease in expression.
Notably, the receptors and ligands responsible for stimuli‑based
apoptosis, including FAS, FASL, FADD, TNF, TNFRSF10B,
TNFRSF1A, Caspase‑8 and Caspase‑8AP2 (RQ≥2) were
found to be increased in a dose‑dependent manner following
luteolin treatment as shown in Fig. 5B (RQ values in Table II).
Luteolin increases Caspase‑3 activity in HeLa cells. Caspases
are vital proteins that modulate the apoptotic response.
Caspase 3 is the primary effector molecule, with the crucial
role of induction of the extrinsic and intrinsic pathway of apop‑
tosis (35). Luteolin treatment upregulated Caspase‑3 activity
in HeLa cells, and the activity increased in a dose‑dependent
manner. Luteolin‑treated HeLa cells exhibited increased
expression of Caspase‑3 activity by 2‑, 4‑ and 8‑fold when
treated with 5, 10 and 20 µM luteolin for 48 h, respectively.
The increase in Caspase activity following luteolin treatment,
in comparison to the control, is shown in Fig. 5C.
Luteolin alters protein expression of apoptotic genes. The
fold‑changes of 35 proteins that are involved in apoptosis,
were investigated using an R&D proteome profiler. Protein
concentration was quantified using a Pierce BCA assay

(Thermo Fisher Scientific, Inc.; cat. no. 23225). Luteolin
significantly upregulated the levels of the pro‑apoptotic
proteins involved in mitochondrial apoptosis, including
HSP6 0, BA D, p ‑p53 (S15), BA X, SM AC/ Diablo,
pro‑Caspase‑3, Cytochrome c and HTRA2/Omi, as well
as increasing the expression of receptors and ligands
responsible for receptor based apoptosis, including TNF
RI/TNFRSF1A, TRAIL R2/DR5, Fas/TNFRSF6/CD95,
FADD, p‑p53 (S392), p‑RAD‑17 (S635), HSP27, TRAIL
R1/DR4, Catalase, p‑Rad17 (S635) and cleaved‑Caspase3
(all exhibiting a fold‑change ≥1.5‑fold with 20 µM luteolin
treatment), while the levels of the anti‑apoptotic proteins,
including Pon2, BCL‑X, cIAP‑2, Clusterin, p27/Kip1,
HIF‑1α, BCL2, cIAP‑1, Claspin and XIAP were all down‑
regulated (all exhibiting a fold‑change ≤0.5 with 20 µM
luteolin treatment); only HSP70 expression was marginally
decreased (Fig. 6; fold‑changes are presented in Table III).
Luteolin modulates the Ras‑Raf/MAPK and AKT/MTOR/PIK3
pathways. The MAPK and the PI3K/AKT/MTOR pathways
serve a crucial role in the regulation of cell growth, differentia‑
tion and cell viability. Cancer development is associated with
aberrant activation of genes in these pathways, and this may
lead to increased cell proliferation and survival. Treatment
of HeLa cells with 10 and 20 µM luteolin for 48 h caused
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Figure 5. Treatment of HeLa cells with 10 and 20 µM luteolin for 48 h resulted in a decrease in various cell cycle regulatory, AKT/MAPK pathway and
apoptotic genes in a dose‑dependent manner. (A) Decrease in cell cycle regulatory and AKT/PI3K and MAPK pathway genes. (B) Increase in the RQ values of
pro‑apoptotic genes and downregulation of anti‑apoptotic genes following treatment with 10 and 20 µM luteolin for 48 h. The results were normalised using the
endogenous control, GAPDH, and the expression in treated samples was compared with DMSO control samples. (C) Analysis of Caspase 3 activity following
treatment with 5, 10 and 20 µM luteolin for 48 h. Luteolin treatment of HeLa cells increases the caspase activity by 2‑, 4‑ and 8‑fold following treatment with
5, 10 and 20 µM for 48 h, respectively. Results depict the caspase activity of treated samples as compared with the DMSO controls. Data are presented as the
mean ± standard deviation of three independent experiments *P<0.05. RQ, relative quantitation.

decreased expression of MAPK pathway genes, including
MAPK1, MAK14, MAPK3 and MAP3K5, as well as decreased
expression of AKT/MTOR/PIK3 pathway genes, such as
AKT1, AKT2, MTOR, PIK3CD, PIK3C2A and PIK3C2B (all
with an RQ≤0.5; Fig. 5A and Table I).
Luteolin alters the phosphorylation of proteins involved in the
AKT signaling pathway. An AKT pathway phosphorylated
array (cat. no. AAH‑AKT‑1‑8) was used to assess the effects
of luteolin treatment on phosphorylation of proteins involved
in the AKT pathway. AKT pathway genes were modulated
following treatment with 10 and 20 µM of luteolin for 48 h.
Certain proteins, including P53 (p‑ser241) and P27 (p‑Thr198)
exhibited a marginal increase in fold‑change, while others,
including GSK3a (p‑ser21) and GSK3b (p‑ser9) were not
affected by luteolin treatment. MTOR (p‑ser2448), PRAS 40
(p‑Ther246), BAD (p‑ser112), PTEN (p‑ser380), AKT
(p‑ser473), ERK2 (p‑Y185/Y18, RISK2 (p‑ser386), P70S6k
(p‑Thr421/ser424, PDK1 (p‑ser241) and ERK1 (p‑T202/Y204)
were downregulated. The fold‑changes with respect to the
control are presented in Fig. 7 and Table IV.
Discussion
Despite advances in the early detection of cancer, and devel‑
opments in the prevention and treatment of cancer, it still
remains the principal cause of death worldwide (37). Cancer
treatment includes a wide range of chemotherapeutic drugs
administered either alone or as an adjuvant with surgery or

radiotherapy, and they are extremely effective in killing highly
proliferative cells, including normal cells, and this underlies
many of the associated side effects (19,29,37,38). These
drawbacks highlight the requirement for more specific and
less toxic cancer treatment strategies, including plant‑derived
chemopreventative agents. Several studies have demonstrated
that plant derived bioactive compounds exert their effects
at various stages of cancer, including initiation, promotion
and progression, and may serve as promising preventative or
therapeutic agents. There is a strong association between a
high intake of fruits and vegetables and a decreased risk of
cancer (5,10,11). Various dietary agents, including curcumin,
resveratrol, genistein, chrysin, sulforaphane and various
other flavonoids possess the ability to reverse or attenuate
aberrantly active signaling pathways associated with carci‑
nogenesis (19,28,38‑42). Flavones exhibit strong anticancer
effects in a range of cancer cell lines via regulation of
various molecular mechanisms (14,24,25,43). In addition
to their ability to restore the aberrant signaling of pathways
associated with cancer, flavones may cause cell cycle arrest,
induce apoptosis, and inhibit invasion, metastasis and inflam‑
mation (14,19). Cancer cells may evade apoptosis; therefore,
apoptosis induction by the therapeutic regimen is required,
and this is possible through administration of several different
flavones (14,19,43).
The aim of the present study was to determine the molec‑
ular mechanisms regulated by luteolin in human cervical
cancer cells. Luteolin is the major bioactive compound found
in several different fruits and vegetables, including oregano,
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Table II. Relative quantitation values of apoptotic genes in HeLa cells following treatment with 10 and 20 µM luteolin treatment
for 48 h.
Genes

Ensemble gene no.

APAF1
Hs00559441_m1
FASLG
‑Hs00181225_m1‑
FAS
Hs00163653_m1
CASPASE 8
Hs01018151_m1
CASPASE 8AP2 Hs01594281_m1
FADD
Hs00538709_m1
BAK1
Hs00832876_g1
BAD
Hs00188930_m1
CASPASE 7
‑Hs00169152_m1
DAPK1
Hs00234480_m1
TNFRSF10B
Hs00366272_m1
TNF
Hs00174128_m1
TNFRSF1A
Hs01042313_m1
CASPASE 3
Hs00234387_m1
TRADD
Hs00182558_m1
BID
Hs00609632_m1
BOK
Hs00261296_m1
CASPASE 9
Hs00154260_m1
NOD1
Hs00196075_m1
NOD2
Hs00223394_m1
BCL10
Hs00961847_m1
CARD9
Hs00261581_m1
BCL2L14
Hs00373302_m1
CASP 5
Hs00362072_m1
BAX
Hs00751844_s1
NAIp
Hs01847653_s1
BCL2
Hs00608023_m1
MCL1
Hs00172036_m1
		

Gene description

Luteolin 10 µM

Luteolin 20 µM

Apoptotic peptidase activating factor 1
Fas ligand (TNF)superfamily
Fas (TNF receptor superfamily
Caspase 8
CASP8 associated protein 2
Fas (TNFRSF6)‑associated via death domain
BCL2‑antagonist/killer 1
BCL2‑antagonist of cell death
Caspase 7
Death‑associated protein kinase 1
Tumor necrosis factor receptor superfamily
Tumor necrosis factor (TNF superfamily
Tumor necrosis factor receptor superfamily
Caspase 3
TNFRSF1A‑associated via death domain
BH3 interacting domain death agonist
BCL2‑related ovarian killer
Caspase 9
Nucleotide‑binding oligomerization domain 1
Nucleotide‑binding oligomerization domain 2
B‑cell CLL/lymphoma 10
caspase recruitment domain family
BCL2‑like 14 (apoptosis facilitator)
Caspase 5
BCL2‑associated X protein
NRL family
B‑cell CLL/lymphoma 2
Myeloid cell leukemia sequence 1
(BCL2‑related)

8.00
7.40
6.00
6.00
5.70
5.00
5.00
4.50
4.00
4.00
3.80
3.70
3.70
3.40
3.30
3.00
3.00
2.60
2.20
2.20
2.00
1.70
1.40
1.40
1.40
0.90
0.80
0.29

19.00
12.00
11.00
7.00
7.00
6.00
5.60
5.70
5.00
5.70
9.00
4.00
11.00
3.70
7.60
6.00
12.00
4.30
7.00
4.60
4.00
3.80
3.50
3.20
2.70
0.74
0.29
0.10

Figure 6. Change in expression of apoptotic proteins following treatment with luteolin. (A) Images of the nitrocellulose proteome profiler membrane showing
differences in the expression of apoptotic and cell cycle regulatory proteins in the control and treated samples. (B) Luteolin‑treated (10 and 20 µM for 48 h)
HeLa cells exhibited upregulated expression of pro‑apoptotic proteins and downregulation of anti‑apoptotic proteins in a concentration‑dependent manner.
Fold‑changes of various apoptotic proteins was quantitated by comparison with the dimethyl sulfoxide controls. The data are expressed as the mean ± standard
deviation of three independent experiments. *P<0.05.

parsley and artichoke, and it possesses anti‑neoplastic,
anti‑inflammatory, anti‑microbial, anti‑viral and anti‑diabetic

properties in vitro and in vivo (19,24,26,27,44). The present
study demonstrated that luteolin increased cell death in a
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Table III. Fold‑change in expression of apoptotic proteins
following luteolin treatment (10 and 20 µM for 48 h).
Gene
HSP60
BAD
Phospho‑p53 (S15)
BAX
SMAC/Diablo
TNF RI/TNFRSF1A
TRAIL R2/DR5
Fas/TNFRSF6/CD95
FADD
Procaspase‑3
Cytochrome c
HTRA2/Omi
Phospho‑p53 (S392
HSP27
TRAIL R1/DR4
Catalase
Phospho‑Rad17 (S635)
Cleaved Caspase3
Pon2
BCL‑X
HSP70
cIAP‑2
Clusterin
p27/Kip1
HIF‑1α
BCL2
cIAP‑1
Claspin
XIAP

Luteolin
10 µM

Luteolin
20 µM

2.73
2.50
1.64
1.56
1.53
1.50
1.48
1.44
1.44
1.43
1.41
1.40
1.38
1.47
1.31
1.29
1.20
1.15
0.95
0.82
0.70
0.68
0.67
0.67
0.66
0.63
0.52
0.45
0.30

2.97
6.32
3.43
4.58
2.28
2.46
1.72
1.75
3.36
3.08
3.20
1.94
2.85
2.24
1.71
3.03
2.10
2.85
0.38
0.22
0.67
0.14
0.48
0.42
0.57
0.47
0.16
0.13
0.24

dose‑ and time‑dependent manner, and the IC50 was 20 µM
at 48 h. Treatment of HeLa cells with luteolin caused cell
death that was clearly visible using a microscope, with dying
cells exhibiting rounding off and detaching from the culture
plates. This is in agreement with several other studies, which
have demonstrated that luteolin inhibits the growth of cancer
cells, with an IC50 ranging between 10 and 60 µM based on
cell line (24,29,43‑47). The changes to nuclear morphology
of HeLa cells treated with 10 and 20 µM for 48 h also justi‑
fies the assumption that apoptosis was induced by luteolin,
as nuclear condensation, disintegration, nuclear blebbing and
nuclear debris formation were visualized following luteolin
treatment, while untreated cells did not show any significant
changes in nuclear morphology. Several studies have reported
that flavones, including luteolin, show similar nuclear morpho‑
logical changes in several cancer cell lines, including HeLa,
glioma, EC1 and KYSE450 cells (20,24,48).
DNA fragmentation is a characteristic feature of apoptotic
cells (33), and this was evident in luteolin treated HeLa cells.
Exposure of HeLa cells to 5, 10 and 20 µM luteolin for 48 h

Table IV. Fold changes observed following treatment of HeLa
cells with luteolin concentrations of 10 and 20 µM for 48 h.
Gene
P53(P‑ser241)
P27(P‑Thr198)
GSK3b(P‑ser9)
Mtor(P‑ser2448)
PRAS 40(P‑ther246)
BAD(p‑ser112)
PTEN(P‑ser380)
AKT(P‑ser473)
ERK2(P‑Y185/Y187
RISK2(P‑ser386)
P70S6k(P‑Thr421/ser424
PDK1(P‑ser241)
ERK1(p‑T202/Y204)

Luteolin
10 µM

Luteolin
20 µM

1.46
1.48
0.98
0.67
0.67
0.56
0.62
0.80
0.80
0.66
0.70
0.70
0.65

1.57
1.57
0.68
0.48
0.57
0.45
0.51
0.48
0.50
0.51
0.48
0.48
0.50

resulted in disintegration of the DNA in a ladder‑like pattern,
while intact DNA was observed in the untreated control.
The degree of fragmentation increased in a dose‑dependent
manner when treated for 48 h. Flavonoids, including chrysin
and quercetin, have also been demonstrated to fragment DNA
in different cell lines (20,23,49,50). Cell cycle analysis revealed
that luteolin induced sub‑G1 arrest following treatment with
20 µm for 48 h, in agreement with previous studies, where
arrest at the G2/M or G1 phase was observed when treated
with luteolin in several different cell lines (14,22,24,27,43).
The determination of membrane potential using TMRE and
apoptosis induction by Annexin/PI also supported the notion
that apoptosis was induced by luteolin. Treatment with 5, 10 or
20 µm luteolin for 48 h resulted in mitochondrial depolarization
and Annexin/PI staining showed an increase in the propor‑
tion of cells in early and late apoptosis, and this increased in
a dose‑dependent manner. Several studies have reported that
flavonoids induce DNA fragmentation, decrease mitochondrial
potential and increase the proportion of early and late apop‑
totic cells in various cancer cell lines (20,24,50,51). Notably, it
has also been demonstrated that luteolin decreased the expres‑
sion levels of important cell cycle regulatory genes, including
CCND2, CCND3, CCND1, CCNE2, CDK2, CDK4 and TERT,
and increased the expression of FOXO1 and FOXO3. The
cyclin D proteins, CCNE2 along with CDK4/CDK6 complex,
promotes progression through the G1‑S phase by inhibiting
the retinoblastoma protein. hTERT is responsible for mainte‑
nance of the telomeric ends of the chromosome, and thus, its
downregulation assists in the arrest of cell cycle progression,
and similar results have been reported in different cell lines
following treatments with polyphenols (20,52,53). FOXO1/3
are considered tumor suppressors that increase transcription
of pro‑apoptotic, DNA damage repair and cell cycle regula‑
tory genes, and their expression is decreased in various cancer
cell lines (20,54). FOXO1 is involved in tumor progression
and is significantly associated with late‑stage tumors, and
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Figure 7. Differential expression of phosphorylated proteins in the AKT pathway. (A) Images of the AKT profiler membranes showing differential expression
of the phosphorylated proteins involved in the AKT signaling pathway at 10 and 20 µM of luteolin treatment for 48 h. (B) Luteolin treatment decreased
expression of phosphorylated proteins involved in the AKT signaling pathway, including MTOR (p‑ser2448), PRAS 40 (p‑Ther246), BAD (p‑ser112), PTEN
(p‑ser380), AKT (p‑ser473), ERK2 (p‑Y185/187), RISK2 (p‑ser386), P70S6k (p‑Thr421/ser424), PDK1 (p‑ser241) and ERK1 (p‑T202/Y204), while the expres‑
sion of P53 (p‑ser241) and P27 (p‑Thr198) was increased, all in a dose‑dependent manner (10 and 20 µM). The fold‑changes were calculated by comparing the
treated samples with the DMSO controls. Data are presented as the mean ± standard deviation of three independent experiments *P<0.05.

its expression is important in terms of prognosis of cervical
cancer (20,55).
Pro‑apoptotic and anti‑apoptotic genes are the primary
proteins involved in regulation of apoptosis, and they form
part of the intrinsic and extrinsic apoptotic pathways.
Aberrant expression of these genes contributes toward the
process of carcinogenesis; therefore, these genes may be
targeted for the prevention and treatment of cancer (20,24,51).
Luteolin treatment of HeLa cells resulted in upregulation of
pro‑apoptotic genes involved in the mitochondrial apoptosis
pathway, including APAF1, BAX, BAK1, BAD, BID, BOK,
Caspase7, Caspase9, Caspase 3, NOD1, NOD2, BCL10,
CARD9, BCL2L14 and Caspase 5, as well as extrinsic
pathway genes, including FASLG, FAS, Caspase 8, Caspase
2, FADD, TNFRSF10B, TNF, TNFRSF1A and TRADD, at
the transcriptional level. By contrast, anti‑apoptotic genes,
including BCL2, Mcl1 and NAIP were found to be down‑
regulated in luteolin‑treated HeLa cells. Caspase‑3 is the
primary effector caspase and serves a significant role in the
induction of apoptosis via regulation of the extrinsic and
intrinsic pathways. Treatment with 5, 10 and 20 µM luteolin
for 48 h enhanced the biochemical activity of Caspase‑3 by 2,
4 and 8‑fold, respectively. The association of caspase 3 acti‑
vation with decreased cell survival could be hypothesized
by treating the cells with caspase inhibitor (Z‑VAD‑FMK),
but that was beyond the scope of the present study. However,
Islam et al (35) has reported role of Caspase‑3 in EGCG
mediated apoptosis of Human Chondrosarcoma Cells
(HTB‑94). Numerous studies have demonstrated that flavo‑
noids induce apoptosis by either the intrinsic or extrinsic
pathways (14,19,20,22,48). Additionally, protein expression
of various genes was in agreement with the changes observed
in their gene expression levels. Treatment of HeLa cells with
luteolin resulted in the upregulation of pro‑apoptotic genes
at the protein level, including upregulation of HSP60, BAD,
p‑p53(S15), BAX, SMAC/Diablo, TNF, RI/TNFRSF1A,

TRAILR2/DR5, Fas/TNFRSF6/CD95, FADD, pro‑caspase‑3,
Cytoch rome c, HT R A2/Om i, p‑p53(S392), HSP27,
TRAILR1/DR4, Catalase, p‑Rad17 (S635), cleaved Caspase3
and p53, which is consistent with earlier reports on HeLa
and leukemia cells treated with the flavonoids quercetin and
luteolin (17,20,23). Downregulation of antiapoptotic proteins
at the mRNA/protein level, including Pon2, BCL‑X, HSP70,
cIAP‑2, clusterin, p27/Kip1, HIF‑1α, p21/CIP1/CDKN1A
and BCL2, as well as upregulation of BAX, p‑p53, release
of Cytochrome C, SMAC/DIABLO and cleavage of
Caspase 3, Caspase 9 and PARP1 suggests the involvement
of intrinsic apoptosis. Furthermore, upregulation of recep‑
tors and ligands involved in the extrinsic pathway at the
mRNA/protein level, including TNF, TNFR, RI/TNFRSF1A,
TRAIL R1/DR4, TRAIL R2/DR5, Fas/TNFRSF6/CD95 and
Caspase‑8/Caspase‑8Ap2 highlights the involvement of the
extrinsic pathway. Similar results have been reported when
treated with several different flavonoids and various cell
lines (19,20,56,57). Based on the aforementioned results, it
may be stated that luteolin activates the extrinsic and the
intrinsic pathway of apoptosis, in agreement with certain
previous studies; however, other studies have reported that
luteolin induces either the extrinsic or intrinsic pathway
exclusively (46,47,49). In cancer cells, alterations of p27
protein‑protein interaction alters p27 from a CDK inhibitor
to an oncogene.
Activation of the AKT/RAS‑RAF pathway by phosphor‑
ylation averts apoptosis; however, dephosphorylation likely
induces apoptosis (57,58). BAD is phosphorylated at Ser‑136
and Ser‑112 by AKT and RAS/RAF, respectively (58).
Phosphorylation of BAD leads its association with 14‑3‑3
protein, whereas dephosphorylation of BAD results in its
dimerization with BCL2 family proteins, and accumula‑
tion in the mitochondrial membrane, in turn increasing
apoptosis (59). AKT may further activate other pathways
and molecules, including the MTORC pathway (60), and is
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initiated by various growth factors and cytokines through
receptor tyrosine kinases, including HER, and promotes
cell survival by inactivating pro‑apoptotic proteins and the
forkhead (FoxO1/3a) transcription factors (61). Luteolin
treatment of HeLa cells decreased the expression levels of
important members of AKT/PI3K signaling; specifically,
AKT1, AKT2, MTOR, PIK3CD, PIK3C2A and PIK3C2B
were downregulated. Luteolin also modulated the phosphor‑
ylation of members of the AKT signaling pathway, including
P53 (p‑ser241) and P27 (p‑Thr198), which were significantly
upregulated, while GSK3b (p‑ser9) was slightly down‑
regulated, MTOR (p‑ser2448), PRAS 40 (p‑Ther246), BAD
(p‑ser112), PTEN (p‑ser380) and AKT (p‑ser473) were more
notably downregulated, and ERK2 (p‑Y185/Y187, RISK2
(p‑ser386), P70S6k (p‑Thr421/ser424), PDK1 (p‑ser241) and
ERK1 (p‑T202/Y204) were significantly downregulated.
Several studies have reported similar results; however,
with fewer phosphorylated proteins assessed. Therefore,
the present study is the first to extensively demonstrate
the molecular effects of luteolin‑mediated modification
of phosphorylated proteins involved in the AKT pathway,
to the best of our knowledge (14,18,21). The MAPK
pathway serves a potential role in cell proliferation and
differentiation; luteolin treatment of HeLa cells showed
downregulation of various members of the MAPK signaling
pathway, including MAPK1, MAK14, MAPK3 and MAP3K5,
a substantial decrease in gene expression was observed in
ELK1 and ESR1 together with an increase in PTPRR, which
is an inhibitor of the MAPK pathway. Notably, flavonoids
have been demonstrated to inhibit the AKT/MTOR/MAPK
signaling pathways through modulation of various molecules
involved in these pathways (20,22,48,49,61).
Plant‑derived agents, such as flavonoids, including
luteolin, have proven to be potentially effective options for
the treatment of cancer through modulation of apoptotic path‑
ways. However, the effect of these agents vary notably when
comparing their effects in vitro and in vivo, and this may be
due to their low bioavailability in vivo. Several studies have
attempted to improve the bioavailability of various agents,
with success in certain cases; quercetin treatment using a
nano delivery system improved its effectiveness in in‑vivo
studies (62,63). As the majority of the results cited regarding
luteolin in the present study are based on in vitro and in vivo
studies, and these do not necessarily always accurately repre‑
sent the outcomes observed in humans, additional studies on
the different pharmacokinetic parameters are required, as
well as human clinical trials, before it can be considered a
suitable treatment for cancer. Further study on other cancer
cells, including blood tumor cells, will support the use of
luteolin in a broad spectrum.
In conclusion, the various effects of luteolin highlight its
efficacy on the inhibition of cell proliferation, depolarization
of the mitochondrial membrane potential, induction of cell
cycle arrest and impeding the RAS‑RAF/MAPK/AKT/PI3K
signaling pathway. Therefore, induction of apoptosis in HeLa
cells may qualify it as a potential chemo‑preventive agent.
However, it is first necessary to perform additional in vivo
studies and clinical trials to standardize the dosage and assess
the safety of luteolin, before it can be recommended as a treat‑
ment for cervical cancer treatment.
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